Sorafenib for the treatment of hepatocellular carcinoma across geographic regions

Expert Review of Clinical Pharmacology

Volumn 2, Issue 2, 2009, Pages 129-136

  Hsu, Chiun ^a   Shen, Ying Chun ^a   Cheng, Ann Lii ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Hepatocellular carcinoma; Molecular targeted therapy; Sorafenib

Indexed keywords

PLACEBO; SORAFENIB;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; DESQUAMATION; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; GEOGRAPHIC DISTRIBUTION; HAND FOOT SYNDROME; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; OVERALL SURVIVAL; RASH; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL TIME; TABLET FORMULATION;

EID: 70149103131     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.2.2.129     Document Type: Article

References (54)

1. Jemal A, Murray T, Ward E et al. Cancer statistics 2005. CA Cancer J. Clin. 55, 10-30 (2005).
2. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(Suppl. 1), S5-S16 (2004).
3. Kao JH, Chen DS. Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver Int. 25, 696-703 (2005).
4. Boyault S, Rickman DS, de Reyniès A et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45, 42-52 (2007).
5. Iizuka N, Oka M, Yamada-Okabe H et al. Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res. 62, 3939-3944 (2002).
6. Kim W, Lim SO, Kim JS et al. Comparison of proteome between hepatitis B virus- and hepatitis C virus-associated hepatocellular carcinoma. Clin. Cancer Res. 9, 5493-5500 (2003).
7. Yanaga K. Current status of hepatic resection for hepatocellular carcinoma. J. Gastroenterol. 39, 919-926 (2004).
8. Hsu C, Cheng JC, Cheng AL. Recent advances in non-surgical treatment for advanced hepatocellular carcinoma (HCC). J. Formos. Med. Assoc. 103, 483-495 (2004).
9. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 11, 790-800 (2006).
10. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment. Pharmacol. Ther. 23, 1535-1547 (2006).
11. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48, 1312-1327 (2008).
12. Llovet J, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
13. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia - Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34 (2009).
14. Wilhelm S, Carter C, Lynch M et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Dis. 5, 835-844 (2006).
15. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004).
16. Ito Y, Sasaki Y, Horimoto M et al. Activation of mitogen-activated protein kinases/exgtracellular signal-regulated kinases in human hepatocellular carcinoma Hepatology 27, 951-958 (1998).
17. Huynh H, Nguyen TT, Chow KH et al. Over-expression of the-mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol. 8, 3-19 (2003).
18. Schmitz KJ, Wohlschlaeger J, Lang H et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J. Hepatol. 48, 83-90 (2008).
19. Erhardt A, Hassan M, Heintges T, Haussinger D. Hepatitis C virus core protein induces cell proliferation and activates ERK, JNK, and p38 MAP kinases together with the MAP kinase phosphatase MKP-1 in a HepG2 Tet-Off cell line. Virology 292, 272-284 (2002).
20. Chung TW, Lee YC, Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/ AKT pathways: involvement of invasive potential. FASEB J. 18, 1123-1125 (2004).
21. Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 126, 529-540 (2004).
22. Lee HC, Tian B, Sedivy JM, Wands JR, Kim M. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology 131, 1208-1217 (2006).
23. Yoshida T, Hisamoto T, Akiba J et al. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene 25, 6056-6066 (2006).
24. Chang YS, Adnane J, Trail PA et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother. Pharmacol. 59, 561-574 (2007).
25. Liu L, Cao Y, Chen C et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66, 11851-11858 (2006).
26. Schulze-Bergkamen H, Fleischer B, Schuchmann M et al. Suppression of Mcl-I via RNA interference sensitizes human hepatocellular carcinoma cells toward apoptosis induction. BMC Cancer 6, 232-245 (2006).
27. Rosato RR, Almenara JA, Coe S, Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 67, 9490-9500 (2007).
28. Panka DJ, Wang W, Atkins MB, Mier JW. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res. 66, 1611-1619 (2006).
29. Kim SH, Ricci S, El-Deiry WS. Mcl-1: a gateway to trail sensitization. Cancer Res. 68, 2062-2064 (2008).
30. Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 23, 965-972 (2005).
31. Minami H, Kawada K, Ebi H et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci. 99, 1492-1498 (2008).
32. Clark JW, Eder JP, Ryan D et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res. 11, 5472-5480 (2005).
33. Awada A, Hendlisz A, Gil T et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br. J. Cancer 92, 1855-1861 (2005).
34. Moore M, Hirte HW, Siu L et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann. Oncol. 16, 1688-1694 (2005).
35. Furuse J, Ishii J, Nakachi K Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci. 99, 159-165 (2008).
36. Yamaori S, Yamazaki H, Iwano S et al. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers. Xenobiotica 35, 69-83 (2005).
37. Tateishi T, Watanabe M, Moriya H, Yamaguchi S, Sato T, Kobayashi S. No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem. Pharmacol. 57, 935-939 (1999).
38. Myrand SP, Sekinguchi, K, Man MZ et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin. Pharmacol. Ther. 84, 347-361 (2008).
39. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24, 4293-4300 (2006).
40. Miller AA, Murry DJ, Owzar K et al. Pharmacokinetic (PK) and Phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301. J. Clin. Oncol. 25(18 Suppl.), 3538 (2007).
41. Hsu C, Shen YC, Hu FC, Cheng AL. Geographic difference in clinical trial practice for advanced hepatocellular carcinoma (HCC): implications on trial design of global scale. Ann. Oncol. 19(Suppl. 6), 0-10 (2008).
42. Craxi A, Porta C, Sangiovanni A et al. Efficacy and safety of sorafenib in patients with alcohol-related hepatocellular carcinoma: a sub-analysis from the SHARP trial. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 15591).
43. Bolondi L, Caspary W, Bennouna J et al. Clinical benefit of sorafenib in hepatitis C patients with hepatocellular carcinoma (HCC): subgroup analysis of the SHARP trial. Presented at: 2008 ASCO Gastrointestinal Cancers Symposium, Orlando, FL, USA, 25-27 January 2008 (Abstract 129).
44. Sherman M, Mazzaferro V, Amadori D et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: a subanalysis from the SHARP trial. J. Clin. Oncol 26(Suppl.) (2008) (Abstract 4584).
45. Raoul J, Santoro A, Beaugrand M et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: a subanalysis from the SHARP trial. J. Clin, Oncol. 26(Suppl.) (2008) (Abstract 4587).
46. Galle P, Blanc J, Van Laethem JL et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and prior anti-tumor therapy: a subanalysis from the SHARP trial. J. Hepatol. 48(Suppl. 2), S372 (2008).
47. Abou-Alfa GK, Amadori D, Santoro A et al. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 4518).
48. Dal Lago L, D'Hondt V, Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 13, 845-858 (2008).
49. Abou-Alfa GK, Johnson P, Knox J et al. Preliminary results from a Phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Presented at: 14th European Cancer Conference of the European Cancer Organisation (ECCO). Barcelona, Spain, 23-27 September 2007 (Abstract 3500).
50. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4, 423-436 (2004).
51. Shen YC, Shao YY, Hsu CH et al. Phase II study of sorafenib plus tegafur/uracil (UFT) in patients with advanced hepatocellular carcinoma (HCC). J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 15664).
52. DePrimo SE, Cheng AL, Lanzalone S et al. Circulating biomarkers of sunitinib in patients with unresectable hepatocellular carcinoma (HCC): analysis of correlations with outcome and tumor imaging parameters. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 4593).
53. Zhu AX, Sahani DV, di Tomaso E et al. Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC): insights from a multidisciplinary Phase II study. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 4521).
54. Thomas MB, Chadha R, Iwasaki M, Glover K, Abbruzzese JL. The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). J. Clin. Oncol. 25(18 Suppl.), 4567 (2007).